CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (31,557)	$ (1,528,105)
Adjustments to reconcile to net loss to net cash used in operating activities:
Depreciation and amortization	52,392	111,426
Debt discount amortization	14,546	27,845
Gain on disposal of fixed asset	(988,375)	(639,773)
Impairment of goodwill and inventory	0	544,761
Imputed Interest on RP loans	21,494	31,722
90,000 613,600 Estimated fair value of shares issued for services	90,000	613,600
Decrease (increase) in assets
Prepaid expenses and deposits	(3,228)	(4,457)
Increase (decrease) in liabilities
Accounts Payable	(6,214)	(56,079)
Accrued expenses	(223,144)	86,085
NET CASH USED IN OPERATING ACTIVITIES	(1,074,087)	(812,975)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(10,000)	0
Proceeds from disposal of fixed asset	1,641,073	1,257,037
NET CASH PROVIDED BY INVESTING ACTIVITIES	1,631,073	1,257,037
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the sale of common stock	0	40,000
Proceeds from notes payable - related party	50,000	504,000
Repayments on notes payable - related party	(637,979)	(585,721)
Repayments on notes payable	0	(106,946)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(587,979)	(148,667)
NET CHANGE IN CASH	(30,993)	295,395
EFFECT OF EXCHANGE RATE ON CASH	5,576	(777)
CASH, BEGINNING OF PERIOD	315,826	19,654
CASH, END OF PERIOD	290,409	315,826
Cash paid during the years ended December 31:
Income taxes	980	0
Interest paid	31,622	0
Non-cash investing and financing activities:
Acquisition of Hemprical Genetics with common stock and note payable	$ 0	$ 603,284